BioCentury | Jan 23, 2021
Translation in Brief

Ionis’ ASO therapy for MM; plus epigenetic modification prevents myeloma-associated bone loss and bryostatin analogs reduce neuroinflammation

...deficits in a mouse model of multiple sclerosis.TARGETSEHMT2 (G9A) – Euchromatic histone-lysine N-methyltransferase 2 IRF4 – Interferon...
...Pharmaceuticals Inc. Bellvitge Biomedical Research Institute Johns Hopkins University Stanford University Euchromatic histone-lysine N-methyltransferase 2 (EHMT2) (G9A) Protein kinase C (PKC) Interferon...
BioCentury | Jan 22, 2021
Product Development

Slaoui on Warp Speed’s successes, limitations and lessons a cell-mediated immune response that clears virus infected cells either through secretion of gamma interferon...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

...$50 millionInvestors: Newpath Partners, 8VC, Hatteras Venture Partners and Alexandria Venture InvestmentsCEO: Daniel GettsPatents: UndisclosedTARGETSIFIH1 (MDA5) - Interferon...
BioCentury | Jan 7, 2021

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...said it’s too early to say which indications the company might pursue. A third program targeting interferon...
BioCentury | Dec 31, 2020
Distillery Therapeutics

T cell-specific targeting of KCNA3 for lupus nephritis

...Potassium channel Kv1.3 (KCNA3); protein tyrosine phosphatase receptor type C (PTPRC; CD45; CD45R); CD40 ligand (CD40L; CD40LG; CD154); interferon γ...
BioCentury | Dec 22, 2020
Targets & Mechanisms

Tissue-targeting autoantibodies as a driver of long COVID

...antibodies against IL-18 or the type I interferon...
...survival rates. Additionally, the antibodies against the interferon... higher lung viral levels.TARGETSIFNAR1 (IFNAR) – Interferon...
BioCentury | Dec 3, 2020
Product Development

Over 100 Phase III readouts from COVID-19 therapies possible by 2Q21: Data Byte

Against the backdrop of excitement for COVID-19 vaccines, clinical trials of treatments for infected patients have been mounting. Public databases list 252 Phase III trials of treatments for COVID-19, of which only 25 (10%) had read out as...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Metalloprotease MYSM1 identified as protective factor in lupus

...IL-6, TNFα and CXCL10.TARGET/MARKER/PATHWAY: Myb like, SWIRM and MPN domains 1 (MYSM1); interferon β (IFNB1); interferon-stimulated...
BioCentury | Nov 20, 2020
Translation in Brief

Long-term gene therapy study in dogs with hemophilia A; plus a comparison of HBV vaccine adjuvants and mAb that alleviates chemotherapy side effects

...common gene signature after the second vaccination characterized by positive regulation of genes associated with interferon-related...
BioCentury | Nov 18, 2020
Product Development

COVID-19 Quick Takes: EMA to require more stringent safety monitoring for vaccines; plus J&J, Clover-Thousand Oaks, Medicago-GSK, Inovio and Synairgen

...hold until the company resolves FDA’s questions regarding the CELLETRA 2000 device for vaccine delivery.Inhaled interferon...
...viral signs of infection. The inhaled IFN-β-1a is one of at least two type I interferon... have shown signs of efficacy against COVID-19 in the clinic. Sandi Wong Ad26.COV2.S (JNJ-78436735) INO-4800 Coronavirus VLP (CoVLP, MT-2766) CpG 1018 Interferon...
Items per page:
1 - 10 of 4089